395 related articles for article (PubMed ID: 26259912)
1. Eculizumab in Transplant-Associated Thrombotic Microangiopathy.
Dhakal P; Giri S; Pathak R; Bhatt VR
Clin Appl Thromb Hemost; 2017 Mar; 23(2):175-180. PubMed ID: 26259912
[TBL] [Abstract][Full Text] [Related]
2. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
3. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.
de Fontbrune FS; Galambrun C; Sirvent A; Huynh A; Faguer S; Nguyen S; Bay JO; Neven B; Moussi J; Simon L; Xhaard A; Resche-Riggon M; O'Meara A; Fremeaux-Bacchi V; Veyradier A; Socié G; Coppo P; de Latour RP
Transplantation; 2015 Sep; 99(9):1953-9. PubMed ID: 25651309
[TBL] [Abstract][Full Text] [Related]
4. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
5. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
Transplant Cell Ther; 2024 Jun; 30(6):601.e1-601.e13. PubMed ID: 38521410
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients.
Rudoni J; Jan A; Hosing C; Aung F; Yeh J
Eur J Haematol; 2018 Sep; 101(3):389-398. PubMed ID: 29920784
[TBL] [Abstract][Full Text] [Related]
8. Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus.
Jan AS; Hosing C; Aung F; Yeh J
Transfusion; 2019 Nov; 59(11):3519-3524. PubMed ID: 31587288
[TBL] [Abstract][Full Text] [Related]
9. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy.
Epperla N; Hemauer K; Hamadani M; Friedman KD; Kreuziger LB
Transfusion; 2017 Nov; 57(11):2775-2781. PubMed ID: 28836275
[TBL] [Abstract][Full Text] [Related]
10. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
11. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.
Shochet L; Kanellis J; Simpson I; Ta J; Mulley W
Nephrology (Carlton); 2017 Feb; 22 Suppl 1():23-27. PubMed ID: 28176480
[TBL] [Abstract][Full Text] [Related]
12. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
13. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
14. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
Jodele S; Dandoy CE; Myers K; Wallace G; Lane A; Teusink-Cross A; Weiss B; Davies SM
Bone Marrow Transplant; 2018 Oct; 53(10):1311-1318. PubMed ID: 29674658
[TBL] [Abstract][Full Text] [Related]
15. Use of Eculizumab in Thrombotic Microangiopathy Associated with Hematopoietic Stem Cell Transplantation.
Demircioglu S; Dogan A; Demir C
J Coll Physicians Surg Pak; 2021 Nov; 31(11):1359-1361. PubMed ID: 34689499
[TBL] [Abstract][Full Text] [Related]
16. Transplant-associated thrombotic microangiopathy and immune haematological complications following intestine-containing organ transplantation: experience from over 100 consecutive cases.
Thomas W; Foukaneli T; Cosgrove J; Massey D; Woodward J; Middleton S; Besser M; Russell N; Amin I; Butler A; Sharkey L
Br J Haematol; 2021 Jun; 193(5):961-970. PubMed ID: 33954989
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
18. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?
Jodele S; Laskin BL; Goebel J; Khoury JC; Pinkard SL; Carey PM; Davies SM
Transfusion; 2013 Mar; 53(3):661-7. PubMed ID: 22804695
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Plasma Exchange does not Improve Renal Function in Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy: An Institutional Experience.
Sartain S; Shubert S; Wu MF; Srivaths P; Teruya J; Krance R; Martinez C
Biol Blood Marrow Transplant; 2019 Jan; 25(1):157-162. PubMed ID: 30144562
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant.
Mulay S; Kreuter JD; Bryant SC; Elliott MA; Hogan WJ; Winters JL; Gastineau DA
J Clin Apher; 2015 Jun; 30(3):147-53. PubMed ID: 25230249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
